- Home
- AMAL vs INBX Comparison
AMAL vs INBX Comparison
Compare AMAL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | INBX |
|---|---|---|
| Founded | 1923 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMAL | INBX |
|---|---|---|
| Price | $40.73 | $84.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $33.50 | N/A |
| AVG Volume (30 Days) | ★ 203.4K | 195.3K |
| Earning Date | 01-22-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $305,836,000.00 | $1,400,000.00 |
| Revenue This Year | $10.09 | $563.00 |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $25.03 | $10.81 |
| 52 Week High | $40.89 | $94.57 |
Technical Indicators
Market Signals| Indicator | AMAL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 77.43 | 57.55 |
| Support Level | $37.44 | $70.64 |
| Resistance Level | $39.23 | $88.00 |
| Average True Range (ATR) | 1.36 | 4.98 |
| MACD | 0.33 | 1.24 |
| Stochastic Oscillator | 92.34 | 67.87 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.